Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0T5GT
|
|||
| Former ID |
DNC000395
|
|||
| Drug Name |
CE-1037
|
|||
| Synonyms |
SPWHS19WTL; UNII-SPWHS19WTL; CHEMBL56605; Mdl 201404YA; Mdl 201,404YA; CE 1037; 150493-09-7; ce1037; SCHEMBL8974527; BDBM50058491; Bis(4-(2'-(carboxy-2'-methylpropylsulfonyl)phenyl)2,2'-(1,4-phenylene))diisobutyrate; 3-{4-[2-(4-{1-[4-(2-Carboxy-2-methyl-propane-1-sulfonyl)-phenoxycarbonyl]-1-methyl-ethyl}-phenyl)-2-methyl-propionyloxy]-benzenesulfonyl}-2,2-dimethyl-propionic acid(CE-1037)
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Chronic obstructive pulmonary disease [ICD-11: CA22; ICD-10: J44, J44.9] | Discontinued in Phase 2 | [1] | |
| Structure |
 |
Download2D MOL
|
||
| Formula |
C36H40Na2O12S2
|
|||
| Canonical SMILES |
CC(C)(CS(=O)(=O)C1=CC=C(C=C1)OC(=O)C(C)(C)C2=CC=C(C=C2)C(C)(C)C(=O)OC3=CC=C(C=C3)S(=O)(=O)CC(C)(C)C(=O)[O-])C(=O)[O-].[Na+].[Na+]
|
|||
| InChI |
1S/C36H42O12S2.2Na/c1-33(2,29(37)38)21-49(43,44)27-17-13-25(14-18-27)47-31(41)35(5,6)23-9-11-24(12-10-23)36(7,8)32(42)48-26-15-19-28(20-16-26)50(45,46)22-34(3,4)30(39)40;;/h9-20H,21-22H2,1-8H3,(H,37,38)(H,39,40);;/q;2*+1/p-2
|
|||
| InChIKey |
HTARXGMNANKUGQ-UHFFFAOYSA-L
|
|||
| CAS Number |
CAS 155947-72-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Neutrophil elastase (NE) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Transcriptional misregulation in cancer | |||
| Systemic lupus erythematosus | ||||
| Pathway Interaction Database | Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | |||
| C-MYB transcription factor network | ||||
| Reactome | Collagen degradation | |||
| Degradation of the extracellular matrix | ||||
| Activation of Matrix Metalloproteinases | ||||
| WikiPathways | Hair Follicle Development: Cytodifferentiation (Part 3 of 3) | |||
| Human Complement System | ||||
| Degradation of collagen | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003784) | |||
| REF 2 | Neutrophil elastase inhibitors as treatment for COPD. Expert Opin Investig Drugs. 2002 Jul;11(7):965-80. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.